View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 13, 2022

Successive AdCom wins for bluebird bio cue encouraging signs for rare disease gene therapies

It’s been a turbulent year for gene therapies targeting rare diseases. Could two recent votes for bluebird bio signal a change in fortune?

By William Newton

In back-to-back US Food and Drug Administration (FDA) Advisory Committee (AdCom) meetings last week, panelists voted unanimously in favour of approving bluebird bio’s gene therapies for cerebral adrenoleukodystrophy (CALD) and beta-thalassemia. The biotech sector took note, with bluebird shares soaring by 63.8% when the market opened this morning.

On Thursday, the AdCom voted 15-0 in support of eli-cel for CALD, a rare genetic neurological condition that causes damage to the insulation surrounding nerve cells in the brain. The next day, the committee voted 13-0 to approve beti-cel for beta-thalassemia, a rare blood disorder characterized by a reduced production of hemoglobin.

The AdComs’ complete consensus represented a rare show of unity for a field that has struggled to move forward amid a growing list of safety concerns. Just six months ago, the FDA placed a partial clinical hold on bluebird’s gene therapy lovo-cel for sickle cell disease after a subject developed persistent anemia. The same month, Pfizer paused a trial for its Duchenne muscular dystrophy (DMD) gene therapy candidate following an unexpected death.

But the strong show of support means FDA approvals for eli-cel and beti-cel are likely on the horizon. Though the FDA is not beholden to the AdCom’s recommendations, the agency normally follows suit—especially when there’s a clear consensus. (The recent approval of Biogen’s Aduhelm for Alzheimer’s disease marked one high-profile exception).

The FDA will make its final regulatory decisions for beti-cel and eli-cel by the PDUFA dates of 19 August and 16 September, respectively.

Rocky road for rare disease gene therapies

It’s been a checkered year so far for gene therapies targeting rare diseases, with arguably more downs than ups. In DMD, a rare musculoskeletal disease affecting young boys, industry leaders Pfizer and Sarepta  both  faced safety setbacks for their competing gene therapies. Earlier this month, the National Institutes of Health (NIH) reported an early-stage trial for a gene therapy targeting a rare eye disorder fell short on efficacy– one year after Biogen’s late-stage gene therapy trial for another rare eye condition experienced a similar fate.

As gene therapy trials garnered additional scrutiny, regulators also began taking note. Last September, an FDA AdCom meeting discussed safety concerns over gene therapy delivery vectors and their manufacturing. Meanwhile, the International Society for Cell and Gene Therapy (ISCT) formed a working group following concerns over the misuse of expanded access programs for gene therapies.

Nevertheless, many experts see gene therapies as the most promising opportunity to treat a long list of rare diseases without available treatments. Most rare diseases are caused by single gene mutations, making gene therapies strong candidates to address these glaring unmet needs.

What happens next?

As bluebird bio awaits the FDA’s final decisions on eli-cel and beti-cel, there are still a number of hurdles before these gene therapies can reach patients. Gene therapies can be prohibitively expensive, and experts told Pharmaceutical Technology that beti-cel, marketed as Zynteglo in Europe, could exceed a $1 million price tag in the US. Meanwhile, gene therapies for rare diseases can face a myriad of distribution and delivery obstacles as they navigate complex special pharmacy and insurance industries.

Outside of bluebird, a number of biotechs are nearing the market with their own late-stage gene therapies for rare diseases. According to GlobalData’s Pharmaceutical Intelligence Center, there are 47 late-stage gene therapy candidates targeting rare diseases. This includes 41 candidates at the Phase III stage and six at the pre-registration stage.

As bluebird awaits the final FDA regulatory decision for beti-cel and eli-cel, a host of gene therapies for rare diseases stand to face a similar regulatory environment in the near future.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology